Expression of innate immunity TLR3 and TLR7 receptors at the level of the upper respiratory airways’ mucosa in patients with severe COVID-19

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Human lungs perform critical functions in gas exchange and are a large and complex but vulnerable mucosal surface that interacts with a variety of microorganisms in the environment. Pulmonary cells, including type II pneumocytes and ciliated airway epithelial cells, are the main targets of SARS-CoV-2 infection in the lungs.

Full Text

Restricted Access

About the authors

Natalya D. Abramova

I.I. Mechnikov Scientific Research Institute of Vaccines And Serums of the Ministry of Education and Science of Russia

Email: and960911@gmail.com
ORCID iD: 0000-0002-7307-0515

junior researcher at the Laboratory of molecular immunology, I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Russian Federation, 105064, Moscow,5A Maly Kazenny Lane

Tala D. Soshchenko

I.I. Mechnikov Scientific Research Institute of Vaccines And Serums of the Ministry of Education and Science of Russia

Email: talasoschenko17@gmail.com
ORCID iD: 0009-0000-1665-7734

laboratory researcher at the Laboratory of molecular immunology, I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Russian Federation, 105064, Moscow, 5A Maly Kazenny Lane

Ekaterina A. Meremyanina

I.I. Mechnikov Scientific Research Institute of Vaccines And Serums of the Ministry of Education and Science of Russia

Email: ekaterina@meremianina.ru
ORCID iD: 0000-0003-4334-1473

researcher at the laboratory of molecular immunology, I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Russian Federation, 105064, Moscow, 5A Maly Kazenny Lane

Victoria K. Solntseva

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Email: speak_to_vika@mail.ru
ORCID iD: 0000-0003-3783-9232

PhD in Medical Sciences, senior lecturer at the Department of microbiology, virology and immunology named after academician A.A. Vorobyov, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Russian Federation, 119991, Moscow, 8/2 Trubetskaya Str.

Vadim N. Zheleznyak

I.I. Mechnikov Scientific Research Institute of Vaccines And Serums of the Ministry of Education and Science of Russia; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Email: vng150@mail.ru

PhD in Medical Sciences, senior researcher at the Laboratory for epidemiological analysis and monitoring of infectious diseases, I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Russian Federation, 105064, Moscow, 5A Maly Kazenny Lane Moscow; 119991, Moscow, 8/2 Trubetskaya Str.

Oksana A. Svitich

I.I. Mechnikov Scientific Research Institute of Vaccines And Serums of the Ministry of Education and Science of Russia; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Author for correspondence.
Email: svitichoa@yandex.ru
ORCID iD: 0000-0003-1757-8389

MD, professor of RAS, corresponding member of RAS, professor of the Department of microbiology, virology and immunology named after academician A.A. Vorobyov of F.F. Erisman Institute of Public Health of I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University), director of I.I. Mechnikov Scientific Research Institute of Vaccines and Serums of the Ministry of Education and Science of Russia

Russian Federation, 105064, Moscow, 5A Maly Kazenny Lane Moscow; 119991, Moscow, 8/2 Trubetskaya Str.

References

  1. Bortolotti D., Gentili V., Rizzo S. et al. SARS-CoV-2 spike 1 protein controls natural killer cell activation via the HLA-E/NKG2A pathway. Cells. 2020; 9(9): E1975. https://dx.doi.org/10.3390/cells9091975.
  2. Li F. Receptor recognition and cross-species infections of SARS coronavirus. Antiviral Res. 2013; 100(1): 246–54. https://dx.doi.org/10.1016/j.antiviral.2013.08.014.
  3. Khanmohammadi S., Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. J Med Virol. 2021; 93(5): 2735–39. https://dx.doi.org/10.1002/jmv.26826.
  4. Меремьянина Е.А., Свитич О.А. Иммуногенетика COVID-19. В кн.: Абрамова Н.Д., Ахматова Н.К., Бишева И.В. с соавт. Мукозальный иммунитет у пациентов с COVID-19: лечение и реабилитация. Под ред. Костинова М.П., Свитича О.А., Чучалина А.Г. М.: Группа МДВ. 2022; с. 9–26. [Meremyanina E.A., Svitich O.A. Immunogenetics of COVID-19. In: Abramova N.D., Akhmatova N.K., Bisheva I.V. et al. Mucosal immunity in patients with COVID-19: Treatment and rehabilitation. Ed. by Kostinov M.P., Svitich O.A., Chuchalin A.G. Moscow: MDV Group. 2022; pp. 9–26 (In Russ.)]. ISBN: 978-5-906748-20-1. EDN: ZVNHWK.
  5. Yamamoto M., Sato S., Hemmi H. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003; 301(5633): 640–43. https://dx.doi.org/10.1126/science.1087262.
  6. Velloso F.J., Trombetta-Lima M., Anschau V. et al. NOD-like receptors: Major players (and targets) in the interface between innate immunity and cancer. Bioscience Reports. 2019; 39(4): BSR20181709. https://dx.doi.org/10.1042/BSR20181709.
  7. de Groot N.G., Bontrop R.E. COVID-19 pandemic: Is a gender-defined dosage effect responsible for the high mortality rate among males? Immunogenetics. 2020; 72(5): 275–77. https://dx.doi.org/10.1007/s00251-020-01165-7.
  8. Kayesh M.E.H., Kohara M., Tsukiyama-Kohara K. An overview of recent insights into the response of TLR to SARS-CoV-2 infection and the potential of TLR agonists as SARS-CoV-2 vaccine adjuvants. Viruses. 2021; 13(11): 2302. https://dx.doi.org/10.3390/v13112302.
  9. Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol. 2020; 92(10): 2105–13. https://dx.doi.org/10.1002/jmv.25987.
  10. Bastard P., Levy R., Henriquez S. et al. Interferon-β therapy in a patient with Incontinentia Pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2. J Clin Immunol. 2021; 41(5): 931–33. https://dx.doi.org/10.1007/s10875-021-01023-5.
  11. Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10): a016295. https://dx.doi.org/10.1101/cshperspect.a016295.
  12. Rudd B.D., Smit J.J., Flavell R.A. et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol. 2006; 176(3): 1937–42. https://dx.doi.org/10.4049/jimmunol.176.3.1937.
  13. Poulas K., Farsalinos K., Zanidis C. Activation of TLR7 and innate immunity as an efficient method against COVID-19 pandemic: Imiquimod as a potential therapy. Front Immunol. 2020; 11: 1373. https://dx.doi.org/10.3389/fimmu.2020.01373.
  14. Said E.A., Tremblay N., Al-Balushi M.S. et al. Viruses seen by our cells: The role of viral RNA sensors. J Immunol Res. 2018; 2018: 9480497. https://dx.doi.org/10.1155/2018/9480497.
  15. Swiecki M., Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015; 15(8): 471–85. https://dx.doi.org/10.1038/nri3865.
  16. Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun. 2020; 12(1): 4–20. https://dx.doi.org/10.1159/000503030.
  17. Nguyen H., Gazy N., Venketaraman V. A role of intracellular Toll-like receptors (3,7, and 9) in response to Mycobacterium tuberculosis and co-infection with HIV. Int J Mol Sci. 2020; 21(17): E6148. https://dx.doi.org/10.3390/ijms21176148.
  18. Alturaiki W., Alkadi H., Alamri S. et al. Association between the expression of toll-like receptors, cytokines, and homeostatic chemokines in SARS-CoV-2 infection and COVID-19 severity. Heliyon. 2023; 9(1): e12653. https://dx.doi.org/10.1016/j.heliyon.2022.e12653.
  19. Mohanty M.C., Varose S.Y., Sawant U.P., Fernandes M.M. Expression of innate immune response genes in upper airway samples of SARS-CoV-2 infected patients: A preliminary study. Indian J Med Res. 2021; 153(5&6): 677–83. https://dx.doi.org/10.4103/ijmr.IJMR_131_21.
  20. de la Rica R., Borges M., Gonzalez-Freire M. COVID-19: In the eye of the cytokine storm. Front Immunol. 2020; 11: 558898. https://dx.doi.org/10.3389/fimmu.2020.558898.
  21. Moreno-Eutimio M.A., Lopez-Macias C., Pastelin-Palacios R. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 2020; 22(4): 226–29. https://dx.doi.org/10.1016/j.micinf.2020.04.009.
  22. Schmitz M.L., Kracht M., Saul V.V. The intricate interplay between RNA viruses and NF-κB. Biochim Biophys Acta. 2014; 1843(11): 2754–64. https://dx.doi.org/10.1016/j.bbamcr.2014.08.004.
  23. Liu T., Zhang L., Joo D., Sun S.C. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017; 2: 17023. https://dx.doi.org/10.1038/sigtrans.2017.23.
  24. Takaoka A., Yamada T. Regulation of signaling mediated by nucleic acid sensors for innate interferon-mediated responses during viral infection. Int Immunol. 2019; 31(8): 477–88. https://dx.doi.org/10.1093/intimm/dxz034.
  25. Yanai H., Chiba S., Hangai S. et al. Revisiting the role of IRF3 in inflammation and immunity by conditional and specifically targeted gene ablation in mice. Proc Natl Acad Sci U S A. 2018; 115(20): 5253–58. https://dx.doi.org/10.1073/pnas.1803936115.
  26. Totura A.L., Whitmore A., Agnihothram S. et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015; 6(3): e00638-00615. https://dx.doi.org/10.1128/mBio.00638-15.
  27. Nature Immunology. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.URL: https://www.nature.com/articles/ni.1863 (date of access – 23.09.2022).
  28. Han L., Zhuang M.W., Deng J. et al. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5–MAVS, TLR3–TRIF, and cGAS–STING signaling pathways. J Med Virol. 2021; 93(9): 5376–89. https://dx.doi.org/10.1002/jmv.27050.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies